natgillin/translations-raw huggingface dataset:
The hybrid fuel supply system according to any one of claims 1 to 4, further comprising a fuel pump (320,2) provided in the LNG cargo tank (CT,1) and configured to supply the LNG stored in the LNG cargo tank (CT,1) to the high pressure pump (300,120). 
Sustav za slanje hibridnog goriva u skladu s bilo kojim od patentnih zahtjeva 1 do 4, naznačen time što dodatno uključuje crpku za gorivo (320,2), smještenu u spremniku za LNG kao teret (CT,1) i konfiguriranu za slanje LNG-a spremljenog u spremniku za LNG kao teret (CT,1) u visokotlačnu crpku (300,120).
The hybrid fuel supply system according to any one of claims 1 to 5, wherein a reliquefaction system using a separate refrigerant cycle is not provided for reliquefaction of the BOG. 
Sustav za slanje hibridnog goriva u skladu s bilo kojim od patentnih zahtjeva 1 do 5, naznačen time što sustav za ponovno ukapljivanje gdje se upotrebljava kruženje odvojenog rashladnog sredstva nije predviđen za ponovno ukapljivanje BOG-a.
The hybrid fuel supply system according to any one of claims 1 to 7, wherein when the vessel is in a ballast condition, the engine (100,3) of the vessel is supplied with the LNG compressed by the high pressure pump (300,1120) as fuel. 
Sustav za slanje hibridnog goriva u skladu s bilo kojim od patentnih zahtjeva 1 do 7, naznačen time što kada je brod u balastnom stanju, brodski motor (100,3) prima LNG komprimiran visokotlačnom crpkom (300,1120) kao gorivo.
The hybrid fuel supply system according to any one of claims 1 to 9, wherein the vessel is an LNG carrier having a capacity of 130,000 to 350,000 m3. 
Sustav za slanje hibridnog goriva u skladu s bilo kojim od patentnih zahtjeva 1 do 9, naznačen time što je brod LNG brod, s nosivošću od 130.000 do 350.000 m3.
The compound of Claim 1, wherein the crystalline form is Compound 1 free base dichloromethane solvate, characterized by a powder X-ray diffraction pattern having at least one peak selected from those at 5.9, 7.1, 9.6, 10.0, 10.7, 11.1, 13.2, 14.8, and 18.2 degrees 2θ, each peak being ± 0.2 degrees 2θ (pattern E), when measured at about 25°C with Cu Ka radiation at 1.54178 Å. 
Spoj u skladu s patentnim zahtjevom 1, pri čemu je kristalni oblik slobodna baza diklormetanskog solvata Spoja 1, naznačen time, da ga karakterizira rendgenski difraktogram praha koji ima najmanje jedan pik odabran od sljedećih vrijednosti: 5.9, 7.1, 9.6, 10.0, 10.7, 11.1, 13.2, 14.8 i 18.2 stupnjeva 2θ, pri čemu je svaki vrh ± 0.2 stupnjeva 2θ(uzorak E), izmjereno pri približno 25 °C uz Cu Ka zračenje na 1,54178 Å .
The compound or salt of any one of Claims 1 to 17, or a pharmaceutical composition comprising the compound or salt of any one of Claims 1 to 17 and one or more pharmaceutically acceptable excipients, for use in a method for treating a disease characterized by apoptotic dysfunction and/or overexpression of an anti-apoptotic Bcl-2 family protein wherein the disease is a neoplastic, immune, or autoimmune disease. 
Spoj ili sol u skladu s bilo kojim od patentnih zahtjeva 1 do 17, ili farmaceutski pripravak koji sadržava spoj ili sol u skladu s bilo kojim od patentnih zahtjeva 1 do 17 i jedan ili više farmaceutski prihvatljivih pomoćnih tvari, namijenjen upotrebi u postupku liječenja bolesti, naznačen time, da je riječ o apoptoznoj disfunkciji i / ili prekomjernoj ekspresiji proteina iz obitelji anti-apoptotičnog Bcl-2 pri čemu je bolest neoplastična, imuna ili autoimuna bolest.
The compound or salt or pharmaceutical composition for the use of Claim 20, wherein the disease is a lymphoid malignancy. 
Spoj ili sol ili farmaceutski pripravak za uporabu u skladu s patentnim zahtjevom 20, naznačen time, da bolest je limfoidni maligni tumor.
The compound or salt or pharmaceutical composition for the use of Claim 20, wherein said method comprises administration of said compound or salt or said pharmaceutical composition orally in a dose of about 50 to about 1000 mg Compound 1 or a salt thereof per day at an average treatment interval of about 3 hours to about 7 days. 
Spoj, sol ili farmaceutski pripravak za uporabu u skladu s patentnim zahtjevom 20, naznačen time, da navedeni postupak obuhvaća davanje navedenog spoja ili soli ili farmaceutskog pripravka oralno u dozi od oko 50 do oko 1000 mg spoja 1 ili njegove soli po danu uz prosječni interval liječenja od oko 3 sata do oko 7 dana.
The compound or salt or pharmaceutical composition for the use of Claim 20, wherein said method comprises administration of said compound or salt or said pharmaceutical composition orally once daily in a dose of about 200 to about 400 mg Compound 1 free base equivalent per day. 
Spoj, sol ili farmaceutski pripravak za uporabu u skladu s patentnim zahtjevom 20, naznačen time, da navedeni postupak obuhvaća davanje navedenog spoja ili soli ili farmaceutskog pripravka oralno jednom dnevno u dozi od oko 200 do oko 400 mg ekvivalenta slobodne baze Spoja 1 po danu.
A dispersion of the compound or salt of any one of Claims 1 to 17 for use in a method for treating a disease characterized by apoptotic dysfunction and/or overexpression of an anti-apoptotic Bcl-2 family protein, wherein the disease is a neoplastic, immune, or autoimmune disease. 
Disperzija spoja ili soli u skladu s bilo kojim od patentnih zahtjeva 1 do 17, namijenjena upotrebi u postupku liječenja bolesti, naznačena time, da je riječ o apoptoznoj disfunkciji i/ili prekomjernoj ekspresiji proteina iz obitelji anti-apoptotičnog Bcl-2 pri čemu je bolest neoplastična, imuna ili autoimuna bolest.
The dispersion for the use of Claim 27, wherein said method comprises administration of said dispersion orally in a dose of about 50 to about 1000 mg Compound 1 or a salt thereof per day at an average treatment interval of about 3 hours to about 7 days. 
Disperzija za uporabu u skladu s patentnim zahtjevom 27, naznačena time, da navedeni postupak obuhvaća davanje navedene disperzije oralno u dozi od oko 50 do oko 1000 mg Spoja 1 ili njegove soli po danu u prosječnom intervalu tretmana od oko 3 sata do oko 7 dana.
a pharmacologically active ingredient; 
farmakološki aktivni sastojak;
a polyalkylene oxide having a weight average molecular weight of more than 200,000 g/mol; and 
polialkilen oksid koji ima ponderiranu prosječnu molekularnu masu od više od 200,000 g/mol; i
a zinc component, wherein the content of said zinc component is at least 1 parts per million by weight, relative to the total weight of the pharmaceutical dosage form; 
komponentu cinka, pri čemu je sadržaj navedene komponente cinka barem 1 maseni dio na milijun, u odnosu na ukupnu masu farmaceutskog oblika doziranja;
which has a breaking strength of at least 300 N, measured in accordance with the Eur. 
koji ima čvrstoću na lom od barem 300 N, mjereno u skladu s Eur.
The pharmaceutical dosage form according to claim 1, which contains a polyalkylene oxide composition including the polyalkylene oxide and the zinc component, and/or wherein the content of said zinc component is in the range of from 0.01 to 1 mol-% based on the zinc atom content per mol of the alkylene oxide units contained in the polyalkylene oxide. 
Farmaceutski oblik doziranja prema zahtjevu 1, naznačen time da sadrži pripravak polialkilen oksida koji sadrži polialkilen oksid i komponentu cinka, i/ili pri čemu je sadržaj navedene komponente cinka u rasponu od 0.01 do 1 mol-% bazirano na sadržaju cinkovih atoma po molu jedinica alkilen oksida sadržanih u polialkilen oksidu.
press-forming the mixture obtained in step (a) with preceding, simultaneous, or subsequent exposure to heat. 
oblikovanje prešanjem smjese dobivene u koraku (a) uz prethodno, istovremeno, ili naknadno izlaganje toplini.
The compound according to claim 1 or claim 2, having Formula Ia: and pharmaceutically acceptable solvates thereof, wherein: is H, F or methyl; 
Spoj sukladno zahtjevu 1 ili zahtjevu 2, Formule Ia: [image] ili njegov farmaceutski prihvatljiv solvat, pri čemu: je H, F ili metil;
follicular maturation arrest, atresia, anovulation, dysmenorrhea, dysfunctional uterine bleeding, infertility), androgen-producing tumor (virilizing ovarian or adrenal tumor), menorrhagia and adenomyosis. 
prestanak sazrijevanja folikula, atresija, anovulacija, dismenoreja, disfunkcionalno materično krvarenje, neplodnost), tumor koji proizvodi androgen (virilizirajući tumor jajnika ili virilizirajući adrenalni tumor), menoragiju i adenomiozu.
PG represents a suitable protecting group such as for example DMB, PMB, Boc, allyl, diphenyl-phosphiramide or 2-trimethylsilylethanesulfonyl; 
PG predstavlja pogodnu zaštitnu skupinu kao što je, na primjer, DMB, PMB, Boc, alil, difenil-fosfinamid ili 2-trimetilsililetansulfonil;
N-acylating compound of Formula (iv) wherein R5' is not H or compound of Formula (v), with a compound of Formula (vi) wherein R1, R1', R2, R2' and R3 are as defined in claim 1; 
N-aciliranje spoja Formule (iv), pri čemu R5’ nije H ili spoja Formule (v), sa spojem Formule (vi) [image] pri čemu su R1, R1’, R2, R2’ i R3 onakvi kao što je definirano u zahtjevu 1;
The compounds according to claim 1 or 2, or tautomers, racemates, enantiomers, diastereoisomers, and mixtures thereof, and pharmaceutically acceptable salts thereof, wherein A is nitrogen atom, R1 is hydrogen; R2 is absent. 
Spojevi sukladno patentnom zahtjevu 1 ili 2, ili tautomeri, racemati, enantiomeri, dijastereomeri, i njihove smjese, i njihove farmaceutski prihvatljive soli, pri čemu je A atom dušika, R1 je vodik; R2 je odsutan.
The compounds according to any one of claims 1 to 4, or tautomers, racemates, enantiomers, diastereoisomers, and mixtures thereof, and pharmaceutically acceptable salts thereof, wherein n is 2. 
Spojevi sukladno patentnom zahtjevu 1 do 4, ili tautomeri, racemati, enantiomeri, dijastereomeri, i njihove smjese, i njihove farmaceutski prihvatljive soli, pri čemu n je 2.
a first pharmacologically active ingredient selected from the compound according to chemical formula (I) and the physiologically acceptable salts thereof, and 
prvi farmakološki aktivni sastojak izabran od spoja prema kemijskoj formuli (I) [image] i njihove fiziološki prihvatljive soli, i
a second pharmacologically active ingredient which is a non-steroidal anti-rheumatic drug selected from the group consisting of indometacin, diclofenac, oxametacin, and aceclofenac, and the physiologically acceptable salts thereof. 
drugi farmakološki aktivni sastojak koji je ne-steroidni anti-reumatski lijek odabran iz skupine koja sadrži indometacin, diklofenak, oksametacin, i aceklofenak, te njihove fiziološki prihvatljive soli.
A kit comprising a first pharmaceutical dosage form comprising the first pharmacologically active ingredient as defined in claim 1 or 2, and a second pharmaceutical dosage form comprising the second pharmacologically active ingredient as defined in claim 1 or 3. 
Komplet koji sadrži prvi farmaceutski oblik doziranja koji sadrži prvi farmakološki aktivni sastojak kako je definiran u zahtjevu 1 ili 2, i drugi farmaceutski oblik doziranja koji sadrži drugi farmakološki aktivni sastojak kako je definiran u patentnom zahtjevu 1 ili 3.
The liquefied gas treatment system according to claim 7, further comprising BOG consuming means configured to receive and uses BOG that is compressed while passing through a part of the plurality of compression cylinders (14) included in the compressor (13). 
Sustav za obradu ukapljenog plina u skladu s patentnim zahtjevom 7, naznačen time što dodatno uključuje element za potrošnju otparenog plina, koji prima i upotrebljava otpareni plin, koji se komprimira prilikom prolaska kroz dio od više kompresijskih cilindara (14) koje sadrži kompresor (13).
The liquefied gas treatment system according to claim 7, wherein the BOG supplied to the sub engine (200) is BOG that is compressed while passing through all or part of the plurality of compression cylinders (14) included in the compressor (13). 
Sustav za obradu ukapljenog plina u skladu s patentnim zahtjevom 7 ili 8, naznačen time što je otpareni plin poslan u izmjenjivač topline (21) otpareni plin, koji se komprimira prilikom prolaska kroz sve ili dio od više kompresijskih cilindara (14) koje sadrži kompresor (13).
The combination according to claim 13, wherein the one or more other therapeutic agents is selected from: bortezomib, carfilzomib, thalidomide, lenalidomide, pomalidomide, cisplatin, carboplatin, pemetrexed, pralatrexate, brentuximab, vendotin, ofatumumab, rituximab, GA101, ibrutinib, GS1101, IPI145, taxol, paclitaxel, alpha folate receptor monoclonal antibodies, CA125 antibodies, elotuzumab, anti CD38 monoclonal antibodies, doxorubicin, idarubicin, cytarabine, fludarabine, gemcitabine, cytarabine, fludarabine, gemcitabine, forodesine, imatinib, dasatinib, ponatinib, nilotinib, temsirolimus, everolimus, CD40 antagonists, CD40 gene medicines, sorafenib, axitinib, CD19/CD3 bifunctional antibodies, conjugated bifunctional antibodies, and bifunctional antibodies recognizing CD epitopes. 
Kombinacija prema bilo kojem zahtjevu 13 ili 14, naznačena time, da je jedno ili više drugih terapeutika odabrano između: boretzomiba, carfilzomiba, talidomida, lenalidomida, pomalidomida, cisplatina, karboplatina, pemetrekseda, pralatreksata, brentuximaba, vendotina, anti CD20 antitijela, ofatumumaba, rituximaba, GA101, ibrutiniba, GS1101, IPI145, taksola, paklitaksela, alfa folatni receptori MAbs-a, CA125 antitijela, elotuzumaba, anti CD38 MAbs-a, doksorubicina, idarubicina, citarabina, fludarabina, gemcitabina, forodezina, imatiniba, dasatiniba, ponatiniba, nilotiniba, temsirolimusa, everolimusa, CD40 antagonistia, CD40 genskih lijekova, sorafeniba, axitiniba i CD19/CD3 također konjugiranih.
A pharmaceutical composition comprising a proton-binding, crosslinked amine polymer comprising the residue of an amine corresponding to Formula 2: 
Farmaceutski pripravak za upotrebu prema bilo kojem od zahtjeva 1-3, naznačen time da umreženi aminski polimer sadrži ostatak amina koji odgovara formuli 2:
The pharmaceutical composition of any of claims 1-6 wherein m is 1-3 and X11 is hydrogen, aliphatic or heteroaliphatic. 
Farmaceutski pripravak za upotrebu prema zahtjevu 9 ili 10, naznačen time da m je 1-3 i X11 je vodik, alifatski ili heteroalifatski ostatak.
The pharmaceutical composition of any of claims 1-5 wherein the crosslinked amine polymer comprises the residue of an amine corresponding to Formula 2b: wherein 
Farmaceutski pripravak za upotrebu prema zahtjevu 1-3, naznačen time da umreženi aminski polimer sadrži aminski ostatak koji odgovara formuli 2b:
The pharmaceutical composition of any preceding claim wherein the crosslinked amine polymer has a chloride ion to phosphate ion binding molar ratio of at least 2:1, respectively, in an aqueous simulated small intestine inorganic buffer ("SIB") containing 36 mM NaCl, 20 mM NaH2PO4, and 50 mM 2-(N-morpholino)ethanesulfonic acid (MES) buffered to pH 5.5 and at 37 °C. 
Farmaceutski pripravak za upotrebu prema bilo kojem od prethodnih zahtjeva naznačen time da umreženi aminski polimer ima odgovarajući molarni omjer vezanja kloridnog iona prema fosfatnom od najmanje 2:1, u vodenom neorganskom puferu koji simulira tanko crijevo ("SIB") koji sadrži 36 mM NaCl, 20 mM NaH2PO4, i 50 mM 2-(N-morfolino)etansulfonske kiseline (MES) puferiran na pH 5,5 i na 37 °C.
The pharmaceutical composition of any preceding claim wherein the crosslinked amine polymer has a proton binding capacity of at least 10 mmol/g and a chloride ion binding capacity of at least 10 mmol/g in an aqueous simulated gastric fluid buffer ("SGF") containing 35 mM NaCl and 63 mM HCl at pH 1.2 and 37 °C. 
Farmaceutski pripravak za upotrebu prema bilo kojem od prethodnih zahtjeva naznačen time da umreženi aminski polimer ima kapacitet vezanja protona od najmanje 10 mmol/g i kapacitet vezanja kloridnog iona od najmanje 10 mmol/g u vodenom puferu koji simulira želučanu tekućinu ("SGF") koji sadrži 35 mM NaCl i 63 mM HCl na pH 1,2 i 37 °C.
The method of claim 1 wherein R10, R20, R30, and R40 are independently hydrogen, aliphatic, aryl, heteroaliphatic, or heteroaryl, m and z are independently 0-3 and n is 0 or 1, and/or wherein X2 is aliphatic or heteroaliphatic. 
Farmaceutski pripravak za upotrebu prema zahtjevu 9, naznačen time da R10, R20, R30 i R40 su neovisno vodik, alifatski, aril, heteroalifatski ostatak ili heteroaril, m i z su neovisno 0-3 i n je 0 ili 1, i/ili X2 je alifatski ili heteroalifatski ostatak.
The method of claim 1 wherein m is 1-3 and X11 is hydrogen, aliphatic or heteroaliphatic. 
Farmaceutski pripravak za upotrebu prema zahtjevu 9 ili 10, naznačen time da m je 1-3 i X11 je vodik, alifatski ili heteroalifatski ostatak.
The method of claim 1 wherein the crosslinked amine polymer comprises the residue of an amine corresponding to Formula 2a: wherein 
Farmaceutski pripravak za upotrebu prema bilo kojem od zahtjeva 1-3, naznačen time da umreženi aminski polimer sadrži aminski ostatak koji odgovara formuli 2a:
The method of claim 9 wherein R11 is independently hydrogen, aliphatic, aminoalkyl, haloalkyl, or heteroaryl, R21 and R31 are independently hydrogen or heteroaliphatic and R41 is hydrogen, aliphatic, aryl, heteroaliphatic, or heteroaryl. The method of claim 9 wherein each R11 is hydrogen, aliphatic, aminoalkyl, or haloalkyl, R21 and R31 are hydrogen or aminoalkyl, and R41 is hydrogen, aliphatic, or heteroaliphatic. The method of claim 1 wherein the crosslinked amine polymer comprises the residue of an amine corresponding to Formula 2b: 
Farmaceutski pripravak za upotrebu prema zahtjevu 12 ili 13, naznačen time da R11 je neovisno vodik, alifatski ostatak, aminoalkil, haloalkil, ili heteroaril, R21 i R31 su neovisno vodik ili heteroalifatski ostatak i R41 je vodik, alifatski, aril, heteroalifatski ostatak ili heteroaril ili određenije farmaceutski pripravak prema zahtjevu 12 ili 13 pri čemu svaki R11 je vodik, alifatski ostatak, aminoalkil ili haloalkil, R21 i R31 su vodik ili aminoalkil i R41 je vodik, alifatski ili heteroalifatski ostatak. Farmaceutski pripravak za upotrebu prema zahtjevu 1-3, naznačen time da umreženi aminski polimer sadrži aminski ostatak koji odgovara formuli 2b:
The method of claim 13 wherein R12 or R42 independently comprise at least one allyl or vinyl moiety. The method of claim 13 wherein (i) m is a positive integer and R12, R22 and R42, in combination comprise at least two allyl or vinyl moieties or (ii) n is a positive integer and R12, R32 and R42, in combination, comprise at least two allyl or vinyl moieties. 
Farmaceutski pripravak za upotrebu prema zahtjevu 15 ili 16, naznačen time da R12 ili R42 neovisno sadrže najmanje jedan alil ili vinil ostatak, ili farmaceutski pripravak prema zahtjevu 15 ili 16 pri čemu (i) m je pozitivni cijeli broj i R12, R22 i R42 u kombinaciji sadrže najmanje dva alil ili vinil ostatka ili (ii) n je pozitivan cijeli broj i R12, R22 i R42 u kombinaciji, sadrži najmanje dva alil ili vinil ostatka.
The method according to claim 1 wherein the crosslinked amine polymer has a chloride ion to phosphate ion binding molar ratio of at least 0.5:1, respectively, in an aqueous simulated small intestine inorganic buffer (“SIB”) containing 36 mM NaCl, 20 mM NaH2PO4, and 50 mM 2-(N-morpholino)ethanesulfonic acid (MES) buffered to pH 5.5 and at 37° C. 
Farmaceutski pripravak za upotrebu prema bilo kojem od prethodnih zahtjeva, naznačen time da umreženi aminski polimer ima odgovarajući molarni omjer vezanja kloridnog iona prema fosfatnom od najmanje 0,5: 1, u vodenom neorganskom puferu koji simulira tanko crijevo ("SIB") koji sadrži 36 mM NaCl, 20 mM NaH2PO4, i 50 mM 2-(N-morfolino)etansulfonske kiseline (MES) puferiran na pH 5,5 i na 37 °C.
The method of claim 1 wherein the crosslinked amine polymer has a chloride ion to phosphate ion binding molar ratio of at least 2:1, respectively, in an aqueous simulated small intestine inorganic buffer (“SIB”) containing 36 mM NaCl, 20 mM NaH2PO4, and 50 mM 2-(N-morpholino)ethanesulfonic acid (MES) buffered to pH 5.5 and at 37° C. 
Farmaceutski pripravak za upotrebu prema bilo kojem od prethodnih zahtjeva naznačen time da umreženi aminski polimer ima odgovarajući molarni omjer vezanja kloridnog iona prema fosfatnom od najmanje 2:1, u vodenom neorganskom puferu koji simulira tanko crijevo ("SIB") koji sadrži 36 mM NaCl, 20 mM NaH2PO4, i 50 mM 2-(N-morfolino)etansulfonske kiseline (MES) puferiran na pH 5,5 i na 37 °C.
The method of claim 1 wherein the crosslinked amine polymer has a proton binding capacity of at least 10 mmol/g and a chloride ion binding capacity of at least 10 mmol/g in an aqueous simulated gastric fluid buffer (“SGF”) containing 35 mM NaCl and 63 mM HCl at pH 1.2 and 37° C. 
Farmaceutski pripravak za upotrebu prema bilo kojem od prethodnih zahtjeva naznačen time da umreženi aminski polimer ima kapacitet vezanja protona od najmanje 10 mmol/g i kapacitet vezanja kloridnog iona od najmanje 10 mmol/g u vodenom puferu koji simulira želučanu tekućinu ("SGF") koji sadrži 35 mM NaCl i 63 mM HCl na pH 1,2 i 37 °C.
z is a non-negative number; and the amine corresponding to Formula 2b comprises at least one allyl group, and 
z je ne negativni broj; i amin koji odgovara formuli 2b sadrži najmanje jednu alil skupinu.
The pharmaceutical composition for use according to any one of claims 1-3 wherein (i) m is a positive integer and R12, R22 and R42, in combination comprise at least two allyl or vinyl moieties or (ii) n is a positive integer and R12, R32 and R42, in combination, comprise at least two allyl or vinyl moieties. 
Farmaceutski pripravak za upotrebu prema zahtjevu 15 ili 16, naznačen time da R12 ili R42 neovisno sadrže najmanje jedan alil ili vinil ostatak, ili farmaceutski pripravak prema zahtjevu 15 ili 16 pri čemu (i) m je pozitivni cijeli broj i R12, R22 i R42 u kombinaciji sadrže najmanje dva alil ili vinil ostatka ili (ii) n je pozitivan cijeli broj i R12, R22 i R42 u kombinaciji, sadrži najmanje dva alil ili vinil ostatka.
The preparation method for the crystalline form of agomelatine according to claim 1 or claim 2, wherein agomelatine compounds of formula (II) or (III) are dissolved in acetic acid, to which acetate is then added, followed by the addition of water dropwise to this reaction mixture, which is then agitated at a temperature of 17-23°C in order to bring about crystallization, with the crystals then being separated from the solution. 
Postupak pripreme kristalnog oblika agomelatina u skladu s patentnim zahtjevom 1, naznačen time, da su spojevi agomelatina formule (II) ili (III) otopljeni u octenoj kiselini, pri čemu se zatim doda acetat, nakon čega se dodaje voda kap po kap u tu reakcijsku smjesu, koja se potom miješa na temperaturi od 17 - 23 °C kako bi se postigla kristalizacija, a kristali su zatim odvojeni od otopine. [image]
The pharmaceutical application of the crystalline form of agomelatine according to claim 1 or 2, wherein the said pharmaceutical application relates to the treatment of sleep disorders, stress, anxiety, seasonal affective disorder, severe depression, cardiovascular diseases, digestive system diseases, insomnia and fatigue brought on by jet lag, schizophrenia, phobias, or depression. 
Kristalni oblik agomelatina u skladu s patentnim zahtjevom 1, naznačen time, da se upotrebljava u postupku liječenja poremećaja spavanja, stresa, anksioznosti, sezonskog afektivnog poremećaja, teške depresije, kardiovaskularnih bolesti, bolesti probavnog sustava, nesanice i umora uslijed vremenske razlike, shizofrenije, fobija ili depresije.
The liquefied gas treatment system according to any one of claims 2 to 6, wherein the compressor (13) includes a plurality of compression cylinders (14). 
Sustav za obradu ukapljenog plina u skladu s patentnim zahtjevom 1, naznačen time što kompresor (150;13) sadrži više kompresijskih cilindara (14).
The liquefied gas treatment system according to claim 7 or 8, wherein the boil-off gas supplied to the heat exchanger (21) is a boil-off gas compressed while passing through all or part of the plurality of compression cylinders (14) included in the compressor (13). 
Sustav za obradu ukapljenog plina u skladu s patentnim zahtjevom 7, naznačen time što se BOG, koji se komprimira kompresorom (150;13), te prebaci u izmjenjivač topline (21), komprimira prilikom prolaska kroz sve ili dio od više kompresijskih cilindara (14) koje sadrži kompresor.